These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 1613572

  • 1. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL, Powe JE, Porter AT.
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [Abstract] [Full Text] [Related]

  • 2. Bone pain palliation with 85Sr therapy.
    Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P.
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [Abstract] [Full Text] [Related]

  • 3. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW, Xie P, Deng HF.
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [Abstract] [Full Text] [Related]

  • 4. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ.
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [Abstract] [Full Text] [Related]

  • 5. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG, Preston DF, Schiefelbein M, Baxter KG.
    JAMA; 1995 Aug 02; 274(5):420-4. PubMed ID: 7542352
    [Abstract] [Full Text] [Related]

  • 6. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 02; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 7. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar 02; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 8. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun 02; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

  • 9. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr 02; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 10. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
    Ouyang W, Liu JH, Liu WY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar 02; 27(3):390-1. PubMed ID: 17426002
    [Abstract] [Full Text] [Related]

  • 11. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D, Yardley J.
    Semin Oncol; 1993 Jun 02; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA.
    Semin Oncol; 1993 Jun 02; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [Abstract] [Full Text] [Related]

  • 13. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan 02; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 14. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
    Blake GM, Gray JM, Zivanovic MA, McEwan AJ, Fleming JS, Ackery DM.
    Br J Radiol; 1987 Jul 02; 60(715):685-92. PubMed ID: 3620827
    [Abstract] [Full Text] [Related]

  • 15. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F, Mognetti T, Resche I.
    Q J Nucl Med; 2001 Mar 02; 45(1):78-83. PubMed ID: 11456379
    [Abstract] [Full Text] [Related]

  • 16. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb 02; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 17. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J, Burkert S.
    Z Urol Nephrol; 1981 Nov 02; 74(11):801-6. PubMed ID: 6172913
    [Abstract] [Full Text] [Related]

  • 18. Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases.
    Bialkowski MM, Wierzbicki JG, Porter AT.
    Cancer Biother Radiopharm; 1997 Oct 02; 12(5):355-62. PubMed ID: 10851487
    [Abstract] [Full Text] [Related]

  • 19. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA.
    Urology; 1997 Nov 02; 50(5):747-53. PubMed ID: 9372886
    [Abstract] [Full Text] [Related]

  • 20. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D, Spaas P, Specenier P.
    Acta Urol Belg; 1996 Sep 02; 64(3):13-9. PubMed ID: 8946776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.